Hansa Biopharma Exec to Discuss Kidney Transplant Innovations at Wedbush Summit
Event summary
- Maria Törnsén, COO and President U.S. of Hansa Biopharma, will participate in a fireside chat at the Wedbush PacGrow Renal Summit on July 8, 2026.
- The session titled 'Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized' will feature Dr. Leonardo Riella from Massachusetts General Hospital.
- Hansa Biopharma is developing imlifidase and HNSA-5487 for kidney transplantation and Guillain-Barré Syndrome, respectively.
The big picture
Hansa Biopharma's participation in the Wedbush PacGrow Renal Summit underscores its focus on addressing unmet medical needs in kidney transplantation. The company's proprietary IgG-cleaving enzyme technology platform positions it as a key player in the immunomodulatory therapies market, which is increasingly important as healthcare systems seek innovative solutions for complex immune disorders.
What we're watching
- Regulatory Approval
- The pace at which imlifidase gains regulatory approval for broader applications beyond highly sensitized kidney patients.
- Market Penetration
- Whether Hansa Biopharma can sustain its market position in the competitive landscape of immunomodulatory therapies.
- Clinical Trials
- How the development of HNSA-5487 for Guillain-Barré Syndrome progresses and its potential impact on the company's portfolio.